ProQR Therapeutics N.V

ProQR Therapeutics N.V. a biotechnology company focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-14-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions as well as other targets in its discovery pipeline. In addition the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center Inserm Transfert SA Ionis Pharmaceuticals Inc. and Leiden University Medical Center as well as license and research collaboration with Eli Lilly and Company for the discovery development and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden the Netherlands.